A new type of immunotherapy that directs patients' immune responses toward tumor cell killing, IMCgp100, showed efficacy in some patients with advanced melanoma.
Among melanoma patients treated with PD-1 inhibitor MK-3475, those whose tumors had the protein PD-L1 had better immune responses and higher survival rates.
Those receiving intervention increased clinical skin exams in the seven months following their education.
Men living alone have more advanced cutaneous malignant melanoma (CMM) at diagnosis and have reduced CMM-specific survival, according to a study.
Research on a technique for detecting the earliest spread of melanoma has confirmed that the procedure significantly prolongs patients' survival rates compared with traditional watch-and-wait techniques.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|